Elanco Animal Health (NYSE:ELAN) Issues FY 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 1.000-1.060 for the period, compared to the consensus estimate of 1.030. The company issued revenue guidance of $5.0 billion-$5.0 billion, compared to the consensus revenue estimate of $4.9 billion. Elanco Animal Health also updated its Q1 2026 guidance to 0.330-0.36 EPS.

Elanco Animal Health Price Performance

Shares of ELAN stock opened at $24.72 on Tuesday. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $26.08. The firm has a market capitalization of $12.28 billion, a price-to-earnings ratio of 412.07, a price-to-earnings-growth ratio of 3.73 and a beta of 1.87. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. The firm has a fifty day moving average of $23.90 and a 200-day moving average of $21.55.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, equities research analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ELAN shares. Piper Sandler upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $24.00 to $30.00 in a research note on Thursday, January 22nd. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Monday, January 19th. Zacks Research cut Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Morgan Stanley raised their price objective on Elanco Animal Health from $18.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, December 18th. Finally, JPMorgan Chase & Co. lifted their target price on Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.89.

Insider Activity at Elanco Animal Health

In other news, insider Rajeev A. Modi bought 4,500 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average cost of $21.33 per share, with a total value of $95,985.00. Following the transaction, the insider directly owned 123,082 shares of the company’s stock, valued at approximately $2,625,339.06. This represents a 3.79% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Robert M. Vanhimbergen acquired 6,950 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were purchased at an average price of $21.64 per share, with a total value of $150,398.00. Following the acquisition, the chief financial officer owned 124,233 shares of the company’s stock, valued at approximately $2,688,402.12. This represents a 5.93% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 43,450 shares of company stock worth $937,883 over the last three months. 0.89% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Elanco Animal Health

Several institutional investors and hedge funds have recently bought and sold shares of ELAN. NewEdge Advisors LLC increased its position in Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after buying an additional 627 shares during the last quarter. Uniplan Investment Counsel Inc. bought a new position in shares of Elanco Animal Health during the 4th quarter worth $41,000. Geneos Wealth Management Inc. increased its holdings in Elanco Animal Health by 53.7% in the 2nd quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock worth $85,000 after acquiring an additional 2,080 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Elanco Animal Health by 26.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company’s stock worth $91,000 after acquiring an additional 1,332 shares during the last quarter. Finally, UMB Bank n.a. raised its stake in Elanco Animal Health by 31.9% in the 4th quarter. UMB Bank n.a. now owns 5,609 shares of the company’s stock valued at $127,000 after acquiring an additional 1,358 shares during the period. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.